← Back to Search

Monoclonal Antibodies

TB006 for Alzheimer's Disease (TB006SAD Trial)

Phase 1
Waitlist Available
Led By David Walling, MD
Research Sponsored by TrueBinding, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day1-day 75

Summary

This trial is testing TB006, a special protein, to see if it is safe and well-tolerated in healthy adults. TB006 aims to help treat Alzheimer's by changing harmful brain processes. T-006, a small-molecule compound derived from tetramethylpyrazine (TMP), has potential for the treatment of neurological diseases.

Eligible Conditions
  • Alzheimer's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day1-day 75
This trial's timeline: 3 weeks for screening, Varies for treatment, and day1-day 75 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of subjects and rate of treatment-emergent adverse events, graded by CTCAE Version 5.0, by dose group and all active treatment vs. placebo
To determine the MTD of single doses of TB006 in healthy adult subjects
To determine the single-dose PK profile of TB006 in healthy adult subjects
Secondary study objectives
Anti-TB006 antibodies
Pharmacokinetic (PK) profile/parameters: Area under the plasma concentration versus time curve (AUC)
Pharmacokinetic (PK) profile/parameters: Area under the plasma concentration versus time curve (AUC) through Day 29
+7 more

Side effects data

From 2022 Phase 1 & 2 trial • 154 Patients • NCT05074498
14%
Blood urea increased
14%
Thyroid function test abnormal
14%
Pyrexia
14%
Gastroenteritis
14%
Sinus tachycardia
14%
Nausea
14%
Asthenia
14%
Fatigue
14%
COVID-19
14%
Insomnia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Part 2: Placebo
Part 1: TB006 140 Milligrams (mg) Weekly (qw)
Part 1: Placebo
Part 1: TB006 420 mg qw
Part 2: TB006 1000 mg qw
Part 1: TB006 1000 mg qw

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TB006 70 mg - 5000 mg IVExperimental Treatment1 Intervention
TB006 infused intravenously over 1 hour
Group II: PlaceboPlacebo Group1 Intervention
0.9% normal saline infused intravenously over 1 hour
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TB006
2021
Completed Phase 2
~160

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

TrueBinding, Inc.Lead Sponsor
5 Previous Clinical Trials
334 Total Patients Enrolled
George Haig, PharmDStudy DirectorTrueBinding, Inc.
5 Previous Clinical Trials
1,278 Total Patients Enrolled
David Walling, MDPrincipal InvestigatorCollaborative Neuroscience Research
1 Previous Clinical Trials
65 Total Patients Enrolled
~11 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top